These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 19032604)

  • 1. Medical treatments for benign prostatic hyperplasia and sexual function.
    Giuliano F
    BJU Int; 2008 Nov; 102 Suppl 2():8-12. PubMed ID: 19032604
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical management of lower urinary tract symptoms with combined medical therapy.
    Roehrborn CG
    BJU Int; 2008 Nov; 102 Suppl 2():13-7. PubMed ID: 19032605
    [No Abstract]   [Full Text] [Related]  

  • 3. Current role of alpha-blockers in the treatment of benign prostatic hyperplasia.
    Kaplan SA
    BJU Int; 2008 Nov; 102 Suppl 2():3-7. PubMed ID: 19032603
    [No Abstract]   [Full Text] [Related]  

  • 4. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?
    Carson CC
    BJU Int; 2006 Apr; 97 Suppl 2():39-43; discussion 44-5. PubMed ID: 16507053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lower urinary tract symptoms and sexual dysfunction: a common approach.
    Giuliano F
    BJU Int; 2008 Mar; 101 Suppl 3():22-6. PubMed ID: 18307682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of alpha-adrenergic inhibitors in treatment of benign prostatic hyperplasia and implications on sexual function.
    Kaplan SA
    Urology; 2004 Mar; 63(3):428-34. PubMed ID: 15028431
    [No Abstract]   [Full Text] [Related]  

  • 7. The effect of alpha-blocker and 5alpha-reductase inhibitor intake on sexual health in men with lower urinary tract symptoms.
    Barqawi AB; Myers JB; O'Donnell C; Crawford ED
    BJU Int; 2007 Oct; 100(4):853-7. PubMed ID: 17662074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Zhao C; Kim SH; Lee SW; Jeon JH; Kang KK; Choi SB; Park JK
    BJU Int; 2011 Jun; 107(12):1943-7. PubMed ID: 21054754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of vardenafil on blood pressure profile of patients with erectile dysfunction concomitantly treated with doxazosin gastrointestinal therapeutic system for benign prostatic hyperplasia.
    Ng CF; Wong A; Cheng CW; Chan ES; Wong HM; Hou SM
    J Urol; 2008 Sep; 180(3):1042-6. PubMed ID: 18639296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Benign prostate hypertrophy and sexual health].
    Randone DF
    Rev Med Suisse; 2007 Mar; 3(104):799-801. PubMed ID: 17503715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Erectile disfunction and benign prostatic hyperplasia - causal relation or coincidence?].
    Gasser T
    Ther Umsch; 2010 Mar; 67(3):145-7. PubMed ID: 20235043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk stratification for benign prostatic hyperplasia (BPH) treatment.
    Emberton M; Fitzpatrick JM; Rees J
    BJU Int; 2011 Mar; 107(6):876-80. PubMed ID: 21265993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selecting therapy for maintaining sexual function in patients with benign prostatic hyperplasia.
    Nehra A
    BJU Int; 2005 Aug; 96(3):237-43. PubMed ID: 16042709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Editorial comment.
    de la Rosette JJ
    Urology; 2010 Jun; 75(6):1458. PubMed ID: 20513508
    [No Abstract]   [Full Text] [Related]  

  • 15. Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds.
    Wong P; Lawrentschuk N; Bolton DM
    Curr Opin Urol; 2009 Jan; 19(1):7-12. PubMed ID: 19057210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?
    Roumeguère T; Zouaoui Boudjeltia K; Hauzeur C; Schulman C; Vanhaeverbeek M; Wespes E
    BJU Int; 2009 Aug; 104(4):511-7. PubMed ID: 19239452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of the simultaneous administration of udenafil and an alpha-blocker in men with erectile dysfunction concomitant with BPH/LUTS.
    Chung BH; Lee JY; Lee SH; Yoo SJ; Lee SW; Oh CY
    Int J Impot Res; 2009; 21(2):122-8. PubMed ID: 19194451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Should we prescribe phosphodiesterase inhibitors for the treatment of symptomatic benign prostatic hyperplasia].
    Caviezel A; Iselin CE
    Rev Med Suisse; 2011 Dec; 7(320):2394-7. PubMed ID: 22232868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Established medical therapy for benign prostatic hyperplasia.
    Auffenberg GB; Helfand BT; McVary KT
    Urol Clin North Am; 2009 Nov; 36(4):443-59, v-vi. PubMed ID: 19942044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system.
    Barendrecht MM; Koopmans RP; de la Rosette JJ; Michel MC
    BJU Int; 2005 Jun; 95 Suppl 4():19-28. PubMed ID: 15871732
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.